Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial - Smit Wm, S. Rodenhuis, E. van der Wall, Harm van Tinteren, M. van de Vijver, E. G. E. de Vries, M. Bontenbal, Lvam V. A. M. Beex, Nooij Ma, D. J. Richel, Voest Ee, M. A. Nooij, Ee E. Voest, E. van der Wall, Peterse Hl - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

American Society of Clinical Oncology, Journal of Clinical Oncology, 16_suppl(23), p. 672-672

DOI: 10.1200/jco.2005.23.16_suppl.672

Links

Tools

Export citation

Search in Google Scholar

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial

Journal article published in 2005 by Smit Wm, S. Rodenhuis, E. van der Wall, Harm van Tinteren, M. van de Vijver, E. G. E. de Vries, M. Bontenbal, Lvam V. A. M. Beex, Nooij Ma, D. J. Richel, Voest Ee, M. A. Nooij, Ee E. Voest, E. van der Wall, Peterse Hl and other authors.

This paper is available in a repository.

This paper is available in a repository.

Full text: Download

Red circle

Preprint: archiving forbidden

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO

Abstract

No abstract available.